Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 study of DRL-1801, a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma.

Next Previous
Trial Profile

Phase 1/2 study of DRL-1801, a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ribrecabtagene autoleucel (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SWASTH

Most Recent Events

  • 21 Oct 2024 New trial record
  • 08 Oct 2024 According to the Aurigene Oncology Media Release, DRL-1801 for the clinical trials is manufactured at the CAR-T GMP manufacturing facility at Aurigene Oncology Limited, Bangalore.
  • 08 Oct 2024 According to the Aurigene Oncology Media Release, results (n=8) of the Phase 1 part of this study were presented at the 21st annual meeting of the International Myeloma Society at Rio De Janeiro, Brazil, held recently.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top